Organon & Co. (NYSE:OGN) Stock Holdings Lifted by KLCM Advisors Inc.

KLCM Advisors Inc. boosted its holdings in Organon & Co. (NYSE:OGN) by 1.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 1,227,649 shares of the company’s stock after buying an additional 11,652 shares during the period. Organon & Co. accounts for approximately 2.1% of KLCM Advisors Inc.’s holdings, making the stock its 9th biggest position. KLCM Advisors Inc.’s holdings in Organon & Co. were worth $18,317,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the business. Prospera Private Wealth LLC bought a new position in shares of Organon & Co. in the third quarter worth about $25,000. Horizon Bancorp Inc. IN raised its stake in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after purchasing an additional 1,585 shares during the period. Versant Capital Management Inc lifted its holdings in Organon & Co. by 92.2% in the 4th quarter. Versant Capital Management Inc now owns 2,760 shares of the company’s stock worth $41,000 after purchasing an additional 1,324 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in Organon & Co. by 32.4% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares during the period. Finally, Abich Financial Wealth Management LLC boosted its stake in Organon & Co. by 5,646.3% in the 3rd quarter. Abich Financial Wealth Management LLC now owns 2,356 shares of the company’s stock worth $45,000 after purchasing an additional 2,315 shares during the period. 77.43% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on OGN shares. TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Barclays decreased their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday. Finally, Morgan Stanley cut their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Friday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Price Performance

Organon & Co. stock opened at $15.30 on Monday. The company has a market cap of $3.94 billion, a price-to-earnings ratio of 3.03, a PEG ratio of 0.83 and a beta of 0.76. The firm’s fifty day moving average is $15.35 and its 200 day moving average is $17.42. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10.

Organon & Co. (NYSE:OGN) last posted its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $1.57 billion. Sell-side analysts forecast that Organon & Co. will post 3.82 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be given a dividend of $0.28 per share. The ex-dividend date of this dividend is Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 7.32%. Organon & Co.’s dividend payout ratio (DPR) is presently 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.